1. How did the board determine the valuation and price paid for Medcan?
2. How did the board determine the valuation and price paid for the remaining 45% of MCL?
3. Can QBL please provide details of the board and management team post the re-organisation.
4. Does the board believe that there is value in the Bauxite tenement? If so, what is the potential value of the project. If not, will the tenement be sold off so that QBL can focus on the MCL business.
Were independent valuation reports commissioned etc?
Questions for QBL - July 2018, page-13
-
- There are more pages in this discussion • 39 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)